SCHEMBL16146409

SCHEMBL16146409

Nc1nc(Nc2cccc(Br)c2)nc2nc[nH]c12

nearest known ligand 0.71

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BRAF P15056 4/20 0.66
POLA1 P09884 2/20 0.64
CDK2 P24941 4/20 0.58
CDK1 P06493 2/20 0.58
CCNB2 O95067 1/20 0.58
CCNB1 P14635 1/20 0.58
CCNA2 P20248 1/20 0.58
CCNA1 P78396 1/20 0.58
CCNB3 Q8WWL7 1/20 0.58
NEK2 P51955 7/20 0.48
JAK2 O60674 2/20 0.47
PDPK1 O15530 1/20 0.47
FLT3 P36888 1/20 0.47
CHEK1 O14757 2/20 0.47
AURKA O14965 2/20 0.47
CHEK2 O96017 1/20 0.47
ABL1 P00519 1/20 0.47
LCK P06239 1/20 0.47
FYN P06241 1/20 0.47
LYN P07948 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16146825 0.85 BRAF (0.59) BRAFPOLA1CDK2CDK1CCNB2
SCHEMBL16146610 0.85 POLA1 (0.71) BRAFPOLA1CDK2CDK1CCNB2
SCHEMBL16146374 0.85 BRAF (0.66) BRAFPOLA1CDK2CDK1NEK2
SCHEMBL16146749 0.84 POLA1 (0.66) POLA1CDK2CDK1CCNB1NEK2
SCHEMBL16147019 0.84 POLA1 (0.65) POLA1CDK2CDK1CCNB2CCNB1
SCHEMBL16146408 0.81 BRAF (0.51) BRAFPOLA1CDK2CDK1CCNB2
SCHEMBL30523380 0.80 BRAF (1.00) BRAF
SCHEMBL16146469 0.80 BRAF (1.00) BRAF
SCHEMBL16146771 0.76 POLA1 (0.53) BRAFPOLA1CDK2CDK1CCNB1
SCHEMBL30523424 0.76 POLA1 (0.53) BRAFPOLA1CDK2CDK1CCNB1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20140303112-A1 Method for treating disease or condition susceptible to amelioration by AMPK activators and compounds of formula which are useful to activate AMP-activated protein kinase (AMPK) ENERGENESIS BIOMEDICAL CO., LTD (TW) 2014-10-09 US claimed
CN-116492347-A Compound for activating AMPK and application thereof 华安医学股份有限公司 2023-07-28 CN disclosed
CN-108703970-A Compound for activating AMPK and application thereof 华安医学股份有限公司 2018-10-26 CN disclosed
US-9938279-B2 Method for treating disease or condition susceptible to amelioration by AMPK activators and compounds of formula which are useful to activate AMP-activated protein kinase (AMPK) ENERGENESIS BIOMEDICAL CO., LTD (TW) 2018-04-10 US disclosed
US-20140303112-A1 Method for treating disease or condition susceptible to amelioration by AMPK activators and compounds of formula which are useful to activate AMP-activated protein kinase (AMPK) ENERGENESIS BIOMEDICAL CO., LTD (TW) 2014-10-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140303112-A1 Method for treating disease or condition susceptible to amelioration by AMPK activators and compounds of formula which are useful to activate AMP-activated protein kinase (AMPK) PRKAG2, PRKAB2, PRKAG1 BRAF 1974/4885POLA1 2876/4885CDK2 1757/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.